Highest-materiality recent filing
OnKure Q1 loss $15.2M; cash $192M; nominates two new PI3Kα inhibitors; halting OKI-219
Net loss of $15.2M ($1.11 per share) for Q1 2026 vs $15.9M ($1.19 per share) in Q1 2025.
OnKure raises $150M in PIPE; plans IND filings for PI3Kα pan-mutant inhibitors in H1 2027
Private placement of ~26.7M shares at $4.15 and ~9.4M pre-funded warrants; gross proceeds ~$150M.
OnKure Therapeutics Q4 2025 net loss narrows to $13.5M; expects March data readouts
Net loss of $13.5M ($0.99/sh) for Q4 2025 vs $17.4M ($1.37/sh) in Q4 2024; expenses decreased.
OnKure Q3 net loss $14.7M; cash $70.3M; initial data from PI3K trial pushed to Q1 2026
Cash $70.3M as of Sept 30, 2025; expected to fund operations into Q4 2026.
OnKure enters ATM offering agreement with Leerink Partners; up to 3% fee
Sales agreement with Leerink Partners for at-the-market offering of Class A common stock.
OnKure reports Q2 net loss $15.4M; OKI-219 trial data expected Q4 2025
Cash $83.4M as of June 30, 2025; runway expected into Q4 2026.
OnKure Q4 2024 net loss $17.4M; cash $110.8M; PIKture-01 data in H2 2025
Net loss Q4 2024 $17.4M ($1.37/share) vs $9.5M ($30.14/share) in Q4 2023; R&D expense rose $5.6M.
OKI-219 well-tolerated in first human trial; no hyperglycemia, Part 1b combo initiated
17 patients dosed across 300–900 mg BID; no dose interruptions, reductions, or discontinuations.
Legacy OnKure posts $35.2M net loss in 9mo; auditor switched to KPMG post-merger
Net loss of $35.2M for nine months ended Sep 30, 2024, vs $25.9M in prior year.
OnKure completes reverse merger with Reneo; trades as OKUR with $65M PIPE
Reneo acquired OnKure in reverse merger; each OnKure common share exchanged for 0.023596 Class A shares.
Reneo stockholders approve all proposals for OnKure merger at special meeting
Proposal 1 (stock issuance for merger) approved: 21.87M for, 110.6K against.
Reneo faces two shareholder lawsuits over OnKure merger proxy; provides supplemental disclosures
Two complaints filed in NY Supreme Court allege misrepresentations/omissions in proxy regarding financial projections and advisor conflicts.
Reneo Pharma terminates CDO Ashley Hall amid planned merger with OnKure
Ashley F. Hall, Chief Development Officer, terminated effective Sept 13, 2024.
Reneo Pharma Q2 net loss $5.4M; merger with OnKure on track for H2 2024
Net loss of $5.4M ($0.16 per share) vs $19.5M ($0.65) in Q2 2023; cash $76.7M at June 30.
OnKure stockholders expected to own ~69.4% of combined entity; Reneo holders ~30.6% on fully-diluted basis.
Reneo Pharmaceuticals initiates strategic alternatives review after failed trial; Q1 net loss $8.4M
STRIDE study of mavodelpar in primary mitochondrial myopathies missed all endpoints in Dec 2023.
STRIDE trial of mavodelpar in primary mitochondrial myopathy failed primary and secondary efficacy endpoints.
Reneo Pharma to cut ~20% workforce, expects $1.7M severance charges in Q1 2024
Second workforce reduction of approximately 20% to be completed by February 29, 2024.
Reneo's mavodelpar fails Phase 3 STRIDE study; cuts workforce 70%
Pivotal STRIDE trial of mavodelpar in primary mitochondrial myopathies missed primary endpoint (12MWT at week 24) and key secondary.
Reneo Q3 net loss $19.2M; STRIDE topline results expected December 2023
Net loss of $19.2M ($0.57/sh) vs $13.0M ($0.53/sh) in Q3 2022; R&D expense up to $13.6M.
Last patient last visit completed in STRIDE study of mavodelpar for primary mitochondrial myopathies; topline data expected December 2023.
Reneo Q2 net loss $19.5M; STRIDE topline results expected Q4 2023
Net loss $19.5M ($0.65/share) vs $12.3M ($0.50) in Q2 2022.
Reneo Pharma Q1 net loss $15.1M; STRIDE enrollment complete, topline 4Q23
Net loss of $15.1M ($0.60/sh) vs $13.0M ($0.53) in Q1 2022.
Reneo Pharmaceuticals prices public offering of 6.875M shares at $8.00, expects net proceeds ~$58.2M
Public offering of 6.875M shares at $8.00/share; underwriters exercised overallotment for 1.031M additional shares in full.
Reneo Pharma reports $93.8M cash; enters non-binding term sheet for up to $100M royalty financing
Preliminary cash, cash equivalents and short-term investments of $93.8M as of March 31, 2023.
Reneo reports Q4 2022 net loss $13.6M; STRIDE study enrollment complete
Full-year 2022 net loss $52.0M ($2.12 per share) vs $39.8M loss in 2021.
Reneo achieves target enrollment in Phase 2b STRIDE trial of mavodelpar; topline Q4 2023
Target enrollment reached in global STRIDE study for mavodelpar in adult PMM patients.
Reneo reports Q3 net loss $13.0M, >80% enrolled in pivotal STRIDE study
Net loss of $13.0M ($0.53 per share) vs $12.7M ($0.52) in Q3 2021.
Reneo Q2 net loss $12.3M; positive LC-FAOD results; STRIDE enrollment two-thirds
Net loss $12.3M ($0.50/share) vs $9.2M ($0.43/share) in Q2 2021.
Reneo Pharma reports Q4 net loss $10.6M; cash $147.7M; no Phase 2 for McArdle
Net loss for Q4 2021 was $10.6M ($0.43 per share) vs $6.3M in Q4 2020; full year net loss $39.8M.
Reneo appoints Michael P. Cruse as COO and Jennifer P. Lam as principal financial officer
Michael P. Cruse appointed COO effective March 2, 2022; base salary increased to $400K (from $350K) and bonus target to 40%.
Reneo Pharmaceuticals CFO Vineet R. Jindal resigns, effective March 31, 2022
CFO Vineet R. Jindal notified resignation on Jan 28, 2022; effective March 31, 2022.
Reneo Pharma Q3 2021 net loss $12.7M; cash $157.7M; trial progress
Net loss of $12.7M ($0.52/share) vs $5.1M ($2.48/share) in Q3 2020.
Effective as of the Effective Time, Nicholas Saccomano and Isaac Manke were appointed as Class I directors, R. Michael Carruthers, Valerie M. Jansen and Edward T. Mathers were appointed as Class II directors and Andrew Phillips and Michael Grey were appointed as Class III directors.
Also on October 4, 2024, Andrew Phillips, Ph.D. was appointed as the Chair of the Board.
Effective as of the Effective Time, Nicholas Saccomano and Isaac Manke were appointed as Class I directors, R. Michael Carruthers, Valerie M. Jansen and Edward T. Mathers were appointed as Class II directors and Andrew Phillips and Michael Grey were appointed as Class III directors.
Effective as of the Effective Time, Nicholas Saccomano and Isaac Manke were appointed as Class I directors, R. Michael Carruthers, Valerie M. Jansen and Edward T. Mathers were appointed as Class II directors and Andrew Phillips and Michael Grey were appointed as Class III directors.
Effective as of the Effective Time, Nicholas Saccomano and Isaac Manke were appointed as Class I directors, R. Michael Carruthers, Valerie M. Jansen and Edward T. Mathers were appointed as Class II directors and Andrew Phillips and Michael Grey were appointed as Class III directors.
Effective as of the Effective Time, Nicholas Saccomano and Isaac Manke were appointed as Class I directors, R. Michael Carruthers, Valerie M. Jansen and Edward T. Mathers were appointed as Class II directors and Andrew Phillips and Michael Grey were appointed as Class III directors.
Effective as of the Effective Time, Nicholas Saccomano and Isaac Manke were appointed as Class I directors, R. Michael Carruthers, Valerie M. Jansen and Edward T. Mathers were appointed as Class II directors and Andrew Phillips and Michael Grey were appointed as Class III directors.
Effective as of the Effective Time, Nicholas Saccomano and Isaac Manke were appointed as Class I directors, R. Michael Carruthers, Valerie M. Jansen and Edward T. Mathers were appointed as Class II directors and Andrew Phillips and Michael Grey were appointed as Class III directors.
the Company terminated the employment of Ashley F. Hall, J.D., the Company’s Chief Development Officer, effective as of September 13, 2024.
each of Mr. Flesher, Mr.Dorenbaum, and Ms. Hall are expected to resign as executive officers of Reneo.
each of Mr. Flesher, Mr.Dorenbaum, and Ms. Hall are expected to resign as executive officers of Reneo.
each of Mr. Flesher, Mr.Dorenbaum, and Ms. Hall are expected to resign as executive officers of Reneo.
Max materiality 1.00 · Median 0.60 · Most common event other_material